Does G57.90 require prior authorization?

No, G57.90 does not require prior authorization (low confidence). No active coverage policies found for this code.

`G57.90` — Unspecified mononeuropathy of unspecified lower limb

ICD-10-CM

No Prior Auth Required

No active coverage policies found for this code (low confidence)

Medical records must clearly document medical necessity for each test and include the reason for referral and a clear diagnostic impression.
Data gathered during NCS should be available showing actual numeric results (latency, amplitude, etc.), preferably in tabular format.
In cases of review, provide a hard copy of waveforms or a complete written report with interpretation upon request.
Normal findings and abnormalities must document muscles tested, presence and type of spontaneous activity, characteristics of voluntary motor unit potentials, and interpretation.

NC-stat testing (CPT 95905) is allowed when the beneficiary has a high pre-test or prior probability of Carpal Tunnel Syndrome (CTS), limited to one service per arm.
Use CPT 95870 for sampling muscles other than the paraspinals associated with the extremities that have been tested.
Molecular genetic testing for identification and management of hereditary transthyretin (TTR) amyloidosis is covered per the referenced Local Coverage Determination L39935.
This billing/coding guidance applies to molecular testing for identification and management of hereditary transthyretin amyloidosis when the test meets the coverage criteria of LCD DL39948.
No clinical indications are specified in this billing/coding guidance; clinical coverage and test appropriateness follow the associated LCD MolDX L39948.
Molecular testing for identification and management of hereditary transthyretin amyloidosis is covered per MolDX LCD DL39950 when billed according to these billing/coding instructions.

A59905 — Billing and Coding: MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis

J05

L39986 — MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis

J05

L39987 — MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis

J05

A59906 — Billing and Coding: MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis

J05

Ask Verity about documentation requirements, denial risks, or coverage in your state.